FIRMQUARRY / COMPANY INTELLIGENCE
['AMGEN SA', 'ABBVIE SPAIN, S.L.U', 'BIOGEN SPAIN S.L.', 'BIOCON BIOLOGICS SPAIN, S.L', 'Sandoz farmacéutica S.A', 'JANSSEN-CILAG, S.A.', 'KERN PHARMA, S.L.', 'ADVANZ PHARMA SPAIN, S.L.', 'FRESENIUS KABI ESPAÑA, S.A.']
Not reported · Verified headquarters unavailable
Track with Pro
Data last updated Oct 22, 2026 · Source: official procurement and company-intelligence sources
General information
- Legal name
- ['AMGEN SA', 'ABBVIE SPAIN, S.L.U', 'BIOGEN SPAIN S.L.', 'BIOCON BIOLOGICS SPAIN, S.L', 'Sandoz farmacéutica S.A', 'JANSSEN-CILAG, S.A.', 'KERN PHARMA, S.L.', 'ADVANZ PHARMA SPAIN, S.L.', 'FRESENIUS KABI ESPAÑA, S.A.']
- First / latest observed
- Nov 3, 2026 — Nov 3, 2026
One source-backed chronology
Timeline
Business change, facilities, workforce, corporate events, and government activity appear chronologically.
- GovernmentAward announced
ACUERDO MARCO DEL SUMINISTRO DE LOS MEDICAMENTOS ADALIMUMAB Y GOLIMUMAB
Disclosed procurement context
Government Business
Money leads this view. Values represent disclosed obligations and procurement amounts—not company revenue.
Global government business
Markets and currencies remain separate; incompatible currencies are never summed.
| Market | Disclosed value | Currency | Latest activity | Processes |
|---|---|---|---|---|
| ESP | 0 | Not reported | Nov 2, 2026 | 1 |
Evidence and identifiers
Sources & Coverage
Technical identifiers live here, with retained official links and visible coverage limitations.
Source identifiers
- OCDS_PARTYeu_ted:59b75944-b000-4489-9073-de1eb7111d7c:a1bdcf35-7f4f-4406-a43c-fffa497ee9be:0 · source ↗